Tailored Health Solutions in Coral Gables, FL At Relive Health, your health goals guide our approach
Together with their obesity-labelled counterparts Wegovy and Zepbound, they generated combined revenues of approximately $69.5 billion in 2025
Results of a 2022 study using the IQVIA LRx database for the United Kingdom (UK) and Germany were similar to those of this study, with 66% to 72% and 71% to 81% of incident and prevalent users, respectively, receiving dulaglutide 1.5 mg post-index [13]
Please consult your personal legal, tax, or financial counsel for information about how this information applies to you or your entity.
Some patients also experience more significant weight loss compared to daily oral semaglutide, but individual results vary
What exactly is glp-1 injections